Is NCT04370587 recruiting in Gilbert, AZ?

Yes, NCT04370587 is currently recruiting participants at its Gilbert, AZ location. This solid tumors clinical trial is actively enrolling qualified participants.

How do I join the solid tumors clinical trial in Gilbert?

To join this clinical trial in Gilbert, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Gilbert clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Solid Tumors Clinical Trial in Gilbert, AZ

Who Can Participate

Inclusion Criteria

Age 18 years or older.

Disease progression after standard of care (SOC) therapy or in the opinion of

The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 - Histologically or pathologically confirmed locally recurrent or metastatic advanced malignancy. Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must have received no more than 3 prior regimens for advanced or metastatic disease. ii. Arm B - locally recurrent or metastatic HNSCC. It must also meet the following criteria: 1) Disease progression to platinum-containing chemotherapy; 2) Failure to anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination. iii. Arm C - Sarcoma. Participants must have received no more than three lines of prior anti-cancer therapies. iv. Arm D - locally recurrent or metastatic cSCC. Participants must have received no more than 3 prior regimens for advanced or metastatic disease. Phase 2a Part 2 i.v. Arm E - Histologically or pathologically confirmed NSCLC that is advanced or recurrent, without EGFR mutation or ALK rearrangement. Participants must have received at least one line but no more than three lines of prior anti-cancer therapies.

Measurable disease per RECIST version 1.1.

Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the opinion of the investigator.

Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Life expectancy \> 12 weeks.

Demonstrate adequate organ function as defined by acceptable laboratory testing results.

Women of child-bearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, while on study treatment, and for six months after receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to W1D1.

Last dose of previous anticancer therapy ≥ 21 days, radiotherapy \> 21 days, or surgical intervention \> 21 days prior to the first dose of T3011.

Recovered from all prior anticancer therapy toxicities.

Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of Assessments.

Capable of understanding and complying with protocol requirements.

Signed and dated institutional review board/independent ethics committee-approved informed consent form before any protocol-directed screening procedures are performed. Key

Exclusion Criteria

Have only uninjectable tumors..

Patients with injectable tumors impinging upon major airways or blood vessels.

HNSCC only: Prior re-irradiation field containing carotid artery.

Greater than 3 distant metastatic lymph node regions and/or metastatic lesions or the largest distant metastases with a diameter of more than 3 cm (non-sarcoma)/5 cm (sarcoma) unless the lesion is to be injected.

Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or gene therapy.

Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease.

Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.

Requires continued concurrent therapy with any drug active against HSV.

Live vaccines, attenuated vaccines within 4 weeks prior to initiation of study treatment (participants vaccinated with inactivated vaccines can be enrolled.

Primary or acquired immunodeficient states.

Pregnant or lactating.

Prior organ transplantation.

Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive serological test at Screening within 14 days of dosing with T3011.

Active autoimmune disease or medical conditions requiring chronic steroid or immunosuppressive therapy within 4 weeks prior to first administration of study treatment.

History of or current central nervous system metastases.

History of seizure disorders within 6 months of Screening.

Active oral or skin herpes lesion at Screening.

Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.

Congestive heart failure, active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina, or clinically significant cardiac arrhythmias.

History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody. 18\. Active infection with SARS-CoV-2 virus. 21. Participants with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention. 22\. Other systemic conditions or organ abnormalities that, in the opinion of the investigator, may interfere with the conduct and/or interpretation of the current study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Gilbert?

Yes, this clinical trial (NCT04370587) has an active research site in Gilbert, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumors Treatment Options in Gilbert, AZ

If you're searching for solid tumors treatment options in Gilbert, AZ, this clinical trial (NCT04370587) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Gilbert research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumors clinical trials near you to find additional studies recruiting in your area.

Solid Tumors Clinical Trial in Gilbert, AZ

Expert Care in Gilbert

IRB Approved

No-Cost Care

Apply for This Gilbert Location

Why Participate?

Simple Process

About This Solid Tumors Study in Gilbert